DE69228949D1 - Tgf-beta zur verbesserung der regeneration von neuronalem gewebe - Google Patents

Tgf-beta zur verbesserung der regeneration von neuronalem gewebe

Info

Publication number
DE69228949D1
DE69228949D1 DE69228949T DE69228949T DE69228949D1 DE 69228949 D1 DE69228949 D1 DE 69228949D1 DE 69228949 T DE69228949 T DE 69228949T DE 69228949 T DE69228949 T DE 69228949T DE 69228949 D1 DE69228949 D1 DE 69228949D1
Authority
DE
Germany
Prior art keywords
tgf
regeneration
beta
improving
neuronal tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69228949T
Other languages
English (en)
Other versions
DE69228949T2 (de
Inventor
Peter Gluckman
Karoly Nikolics
Christopher Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Genentech Inc
Original Assignee
Auckland Uniservices Ltd
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd, Genentech Inc filed Critical Auckland Uniservices Ltd
Publication of DE69228949D1 publication Critical patent/DE69228949D1/de
Application granted granted Critical
Publication of DE69228949T2 publication Critical patent/DE69228949T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69228949T 1991-11-22 1992-11-20 Tgf-beta zur verbesserung der regeneration von neuronalem gewebe Expired - Lifetime DE69228949T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ24069691 1991-11-22
PCT/US1992/009974 WO1993009802A2 (en) 1991-11-22 1992-11-20 Tgf-beta to improve neural outcome

Publications (2)

Publication Number Publication Date
DE69228949D1 true DE69228949D1 (de) 1999-05-20
DE69228949T2 DE69228949T2 (de) 1999-09-16

Family

ID=19923808

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69228949T Expired - Lifetime DE69228949T2 (de) 1991-11-22 1992-11-20 Tgf-beta zur verbesserung der regeneration von neuronalem gewebe

Country Status (9)

Country Link
EP (1) EP0625050B1 (de)
JP (2) JP4101284B2 (de)
AT (1) ATE178801T1 (de)
CA (1) CA2122058C (de)
DE (1) DE69228949T2 (de)
DK (1) DK0625050T3 (de)
ES (1) ES2133333T3 (de)
GR (1) GR3030651T3 (de)
WO (1) WO1993009802A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851832A (en) * 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US6294346B1 (en) 1991-07-08 2001-09-25 Neurospheres Holdings, Ltd. Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents
US6399369B1 (en) 1991-07-08 2002-06-04 Neurospheres Holdings Ltd. Multipotent neural stem cell cDNA libraries
US7166277B1 (en) 1991-07-08 2007-01-23 Neurospheres Holdings Ltd. Remyelination of neurons using multipotent neural stem cell progeny
US7361505B1 (en) 1991-07-08 2008-04-22 Neurospheres Holdings Ltd. Multipotent neural stem cell compositions
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
US5980885A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
US6071889A (en) * 1991-07-08 2000-06-06 Neurospheres Holdings Ltd. In vivo genetic modification of growth factor-responsive neural precursor cells
US5650396A (en) * 1994-03-15 1997-07-22 Celtrix Pharmaceuticals, Inc. Methods of modulating inflammatory cytokines in the CNS using TGF-β
JP2000507939A (ja) 1996-03-22 2000-06-27 ザ ジェネラル ホスピタル コーポレーション 中枢神経系の虚血または外傷後のポリペプチド成長因子の投与
US7544511B2 (en) 1996-09-25 2009-06-09 Neuralstem Biopharmaceuticals Ltd. Stable neural stem cell line methods
CA2296056A1 (en) * 1997-07-10 1999-01-21 Keith Baker Methods for universally distributing therapeutic agents to the brain
US5968829A (en) * 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US8293488B2 (en) 2002-12-09 2012-10-23 Neuralstem, Inc. Method for screening neurogenic agents
AU2003293409A1 (en) 2002-12-09 2004-06-30 Karl K. Johe Method for discovering neurogenic agents
CN103146649B (zh) 2004-06-09 2018-05-22 爱丁堡大学管理处 神经干细胞
US7691629B2 (en) 2004-11-17 2010-04-06 Neuralstem, Inc. Transplantation of human neural cells for treatment of neurodegenerative conditions
US20100158878A1 (en) 2008-12-23 2010-06-24 Alexandra Capela Target populations of oligodendrocyte precursor cells and methods of making and using same
SG187226A1 (en) 2010-07-28 2013-03-28 Neuralstem Inc Methods for treating and/or reversing neurodegenerative diseases and/or disorders
KR102100021B1 (ko) 2014-10-20 2020-04-13 뉴럴스템, 인크. 성장 인자를 코딩하는 외인성 폴리뉴클레오티드를 포함하는 안정한 신경 줄기세포 및 그의 사용 방법

Also Published As

Publication number Publication date
CA2122058C (en) 2001-07-31
DE69228949T2 (de) 1999-09-16
DK0625050T3 (da) 1999-10-25
ES2133333T3 (es) 1999-09-16
WO1993009802A2 (en) 1993-05-27
GR3030651T3 (en) 1999-10-29
ATE178801T1 (de) 1999-04-15
EP0625050A1 (de) 1994-11-23
CA2122058A1 (en) 1993-05-27
JP4101284B2 (ja) 2008-06-18
EP0625050B1 (de) 1999-04-14
JPH07501080A (ja) 1995-02-02
JP2004115532A (ja) 2004-04-15

Similar Documents

Publication Publication Date Title
DE69228949D1 (de) Tgf-beta zur verbesserung der regeneration von neuronalem gewebe
DE69232008D1 (de) Verwendung von insulinähnlichen Wachstumsfaktoren und Analogen zur BEHANDLUNG VON ERKRANKUNGEN DER SEHNERVEN
PT646012E (pt) Cura de feridas e tratamento de perturbacoes fibroticas por tgfbeta-3
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69739792D1 (de) Verfahren zur Behandlung von Augenerkrankungen
SE8703625D0 (sv) New medical use
WO1995017154A3 (en) Use of thalidomide for treating neurocognitive disorders
DE69528773D1 (de) Behandlung von multipler sklerose (ms) und anderen demyelinisationserkrankungen unter verwendung von lofepramin in kombination mit l-phenylalamin, tyrosin oder tryptophan und evtl. einer vitamin b12-verbindung
DE69012261D1 (de) Verwendung von Sertralin zur Behandlung verfrühter Ejakulation.
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE3786893D1 (de) Piperidinderivat zur schmerzbehandlung.
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE69301750D1 (de) Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose
KR890000108A (ko) 종양 치료용 약제학적 조성물
ATE137407T1 (de) Behandlung von intraocularem druck mit einer synergistischen kombination
DE3873188D1 (de) Verwendung von nigerizin zur herstellung eines mittels zur behandlung von virus-erkrankungen.
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69218544D1 (de) Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen
RU97101420A (ru) Способ лечения тонзиллита
DE69941134D1 (de) Verwendung von R (+)- g(a)-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol zur Behandlung von Schlafstörungen
ATE78160T1 (de) Verwendung von ''naftidrofuryl'' zur behandlung von neuropathien.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition